DBV Technologies S.A. (DBVT)
DBV Technologies S.A. (DBVT) from its SEC filings: 2025 revenue $5.6 million (+36% vs the year before), net margin -2607%, free cash flow -$121.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $5.6 million |
| Revenue growth | +36% |
| Net income | -$146.9 million |
| Net margin | -2607.3% |
| Free cash flow | -$121.7 million |
| Diluted EPS | $-1.05 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -53% |
| Cash | $174.9 million |
| Long-term debt | $648,000 |
| Share count, 1 year | +116% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.